Breast cancer dynamics: Molecular signature, Radiotherapy and Nuclear Medicine
It's summertime, and we're about to take you on an exciting journey through the latest advances in breast cancer treatment in a truly multidisciplinary way. We hope you'll enjoy the ride. Stay tuned and have a safe trip!
Decoding biomarkers for more personalized care
Biomarkers in breast cancer management serves as crucial indicators for diagnosis, prognosis and treatment response. They can identify patients who are likely to benefit from specific therapies and monitor treatment efficacy. Advances in biomarkers research through next-generation sequencing are improving precision medicine. Simon NAYLER tells us how this is enabling tailored treatment strategies to improve patient outcomes. We invite you to go deeper in the session section.
Molecular Imaging: at the forefront of innovation
Molecular imaging, such as positron emission tomography (PET), is increasingly used as biomarker to predict and assess treatment response in breast cancer. Willy VANGU explain the potential prognostic value of dual biomarkers in ER positive breast cancer patients. To ensure effective patient care, potential responders to HER-targeted therapy need to be identified. Radionuclide molecular imaging can be a key asset for the detection of overexpression of EGFR (Epidermal Growth Factor Receptor) family members. To complete this interview, you can enjoy the talk of Eric ZERBIB on preoperative assessment with FDG PET Scan in the Session section.
- Where do we stand in developing radionuclides against molecular markers overexpressed on breast cancer (BC) cells such as EGFR-family members?
- As the BCU 2024 co-president, what’s your goal for next edition of the congress end of January 2025?
- What’s the prognostic value of PET scan imaging as a predictive tool for ER + breast cancer patients?
Radiotherapy in early breast cancer
The significance of radiation therapy following neoadjuvant systemic therapy is a topic of ongoing discussion, specifically concerning regional nodal irradiation in patients achieving a complete response. We invite you to go further with Yazid BELKACEMI our next BCU Co-president. He will discuss the number of fractions for delivering a radiation therapy boost which is a critical aspect from a technical perspective, especially when using simultaneous integrated boost and the shift towards moderate hypofractionation. You’ll be able to go further with a comprehensive presentation on ongoing trials in early breast cancer by Sithembile NGIDI in the session section.
